As a licenced pharmaceutical manufacturer UPL is starting to work with our pharmaceutical customers and suppliers to prepare for the implementation of the 2011/62/EU Falsified Medicines Directive. This is a significant piece of legislation with the objective to reduce the risk of counterfeiting within the medicines supply chain.
The first elements of the legislation are effective from 01/01/13 and for UPL the focus will be on suppliers and manufacturers of the raw materials used in pharmaceuticals.
Work will be done to improve the quality assurance of supply and meet the necessary regulatory requirements. Action will then be required as the focus shifts towards changes to packaging components.
As both a personal care and pharmaceutical contract manufacturer, UPL has to accommodate the changes required under the Falsified Medicines Directive alongside the additional changes required in the personal care business by the new EU Cosmetics Regulation 1223/2009 – so it is going to be very busy time as we move towards 2013.